A cost-effectiveness analysis of alternative HIV retesting strategies in sub-Saharan Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 5, 2011, Pages 443-452

  Waters, Richard C ^a   Ostermann, Jan ^a,b   Reeves, Travis D ^c   Masnick, Max F ^a,b   Thielman, Nathan M ^a,b,c   Bartlett, John A ^a,c,d,e   Crump, John A ^a,c,d,e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^e KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE   (Tanzania)

Author keywords

cost effectiveness; guidelines; HIV counseling and testing; retesting; sub Saharan Africa

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; NEVIRAPINE; TENOFOVIR;

ADULT; AFRICA SOUTH OF THE SAHARA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE TRANSMISSION; FEMALE; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MORTALITY; PATIENT CARE; PATIENT COUNSELING; PRIORITY JOURNAL; QUALITY OF LIFE; SECONDARY INFECTION; SENSITIVITY ANALYSIS;

ADULT; AFRICA SOUTH OF THE SAHARA; AIDS SERODIAGNOSIS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; COUNSELING; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MALE; MODELS, ECONOMIC; PREGNANCY; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 79953042530     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182118f8c     Document Type: Article

References (81)

1. De Cock KM, Bunnell R, Mermin J. Unfinished business: expanding HIV testing in developing countries. N Engl J Med. 2006;354:440-442. (Pubitemid 43200293)
2. UNAIDS/WHO Policy Statement on HIV Testing. Geneva: Joint United National Programme on HIV/AIDS, June 2004. Available at http://www.who.int/rpc/research- ethics/hivtestingpolicy-en-pdf.pdf. Accessed November 20, 2010.
3. Denison JA, O'Reilly KR, Schmid GP, et al. HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990-2005. AIDS Behav. 2008;12:363-373.
4. De Cock KM, Marum E, Mbori-Ngacha D. A serostatus approach to HIV/AIDS prevention and care in Africa. Lancet. 2003;362:1847-1849. (Pubitemid 37494765)
5. Grabbe KL, Menzies N, Taegtmeyer M, et al. Increasing access to HIV counseling and testing through mobile services in Kenya: strategies, utilization, and cost-effectiveness. J Acquir Immune Defic Syndr. 2010; 54:317-323.
6. Liechty CA. The evolving role of HIV counseling and testing in resource-limited settings: HIV prevention and linkage to expanding HIV care access. Curr HIV/AIDS Rep. 2004;1:181-185.
7. Matovu JK, Makumbi FE. Expanding access to voluntary HIV counselling and testing in sub-Saharan Africa: alternative approaches for improving uptake, 2001-2007. Trop Med Int Health. 2007;12: 1315-1322. (Pubitemid 350191134)
8. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098.
9. Quinn TC, Mawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921-929. (Pubitemid 30177052)
10. De Cock KM, Gilks CF, Lo YR, et al. Can antiretroviral therapy eliminate HIV transmission? Lancet. 2009;373:7-9.
11. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
12. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40:96-101. (Pubitemid 41233212)
13. UNAIDS. AIDS Epidemic Update. 2009. Available at: http://www.unaids.org/ en/dataanalysis/epidemiology/2009aidsepidemicupdate/. Accessed 15 November 2010.
14. Khobotlo M. Lesotho: HIV Prevention Response and Modes of Transmission Analysis. Maseru, Lesotho National AIDS Commission. Lesotho National AIDS Commission. 2009. Available at: http://siteresources. worldbank.org/INTHIVAIDS/ Resources/375798-1103037153392/Lesotho MOT13April.pdf. Accessed 27 December 2010.
15. Potts M, Halperin DT, Kirby D, et al. Public health. Reassessing HIV prevention. Science. 2008;320:749-750. (Pubitemid 351929614)
16. Landman KZ, Ostermann J, Crump JA, et al. Gender differences in the risk of HIV infection among persons reporting abstinence, monogamy, and multiple sexual partners in northern Tanzania. PLoS One. 2008;3: e3075.
17. Mossdorf E, Stoeckle M, Vincenz A, et al. Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania. Trop Med Int Health. 2010;15:567-573.
18. Marum E, Morgan G, Hightower A, et al. Using mass media campaigns to promote voluntary counseling and HIV-testing services in Kenya. AIDS. 2008;22:2019-2024.
19. Ghana AIDS Commission.National HIV/AIDS Strategic Framework II, 2006-2010. Republic of Ghana. Available at http://www.aidsportal.org/Article- Details.aspx?ID=5211. Accessed November 20, 2010.
20. Zambia HIV National Guidelines: HIV Counselling and Testing. Available at: http://www.zambiahivguide.org/guidelines/zambia-hiv- national-guidelines/ hiv-counseling-and-testing.html?contentInstanceId= 429793. Accessed November 20, 2010.
21. South Africa Country Response. UNAIDS. Available at: http://www. unaids.org/en/CountryResponses/Countries/south-africa.asp. Accessed November 20, 2010.
22. South Africa National AIDS Council. HIV Counselling and Testing Campaign. Available at: http://www.sanac.org.za/Resources-Information- on-HIV-and-AIDS.php. Accessed December 10, 2010.
23. National AIDS and STD Control Programme. National Guidelines for HIV Testing and Counselling in Kenya, 2008. Ministry of Public Health and Sanitation, Kenya. Available at: http://www.aidskenya.org/public-site/webroot/ cache/article/file/National-HTC-Guidelines.pdf. Accessed December 10, 2010.
24. National AIDS Control Programme.National Guidelines for Voluntary Counseling and Testing, 2005. The United Republic of Tanzania. Available at http://www.gf.or.tz/documents-storage/2006-2-6-1-36- 47-national-vct-guidelines. pdf. Accessed December 10, 2010.
25. Bradley H, Tsui A, Kidanu A, et al. Client characteristics and HIV risk associated with repeat HIV testing among women in Ethiopia. AIDS Behav. 2010 Jul 20 [Epub ahead of print].
26. UNAIDS. Voluntary Counseling and Testing (VCT): UNAIDS Technical Update. Geneva: UNAIDS; May 2000.
27. Uganda AIDS Commission. HIV and AIDS: Responses to Frequently Asked Questions. Available at: http://aidsuganda.org/index.php. Accessed November 20, 2010.
28. World Health Organization: Delivering HIV Test Results and Messages for Re-testing. Geneva; WHO 2010.
29. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570-585. (Pubitemid 40204670)
30. Sanders GD, Bayoumi AM, Holodniy M, et al. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med. 2008; 148:889-903. (Pubitemid 351860821)
31. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med. 2005;352:586-595. (Pubitemid 40204671)
32. Tole SP, Sanders GD, Bayoumi AM, et al. Cost-effectiveness of voluntary HIV screening in Russia. Int J STD AIDS. 2009;20:46-51.
33. Paltiel AD, Walensky RP, Schackman BR, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145:797-806. (Pubitemid 351650333)
34. Walensky RP, Wood R, Fofana MO, et al. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr. 2011;56:26-35.
35. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1-17; quiz CE11-14.
36. Qaseem A, Snow V, Shekelle P, et al. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med. 2009;150:125-131.
37. Mermin J, Musinguzi J, Opio A, et al. Risk factors for recent HIV infection in Uganda. JAMA. 2008;300:540-549.
38. Peterson L, Nanda K, Opoku BK, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One. 2007;2:e1312.
39. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358:1560-1571. (Pubitemid 351519816)
40. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643-656. (Pubitemid 46281312)
41. van Loggerenberg F, Mlisana K, Williamson C, et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One. 2008;3:e1954.
42. South Africa Country Mortality Data, 2005. World Health Organization. Available at: http://www.who.int/healthinfo/morttables/en/index.html. Accessed November 20, 2010.
43. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276: 1253-1258. (Pubitemid 26337709)
44. CASCADE Collaboration. Differences in CD4 cell counts at serocon-version and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr. 2003;34:76-83.
45. Kiwanuka N, Robb M, Laeyendecker O, et al. HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J Acquir Immune Defic Syndr. 2010;54:180-184.
46. Korenromp EL, Williams BG, Schmid GP, et al. Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection-a quantitative review. PLoS One. 2009;4:e5950.
47. Morgan D, Mahe C, Mayanja B, et al. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS. 2002;16:597-603. (Pubitemid 34218855)
48. Urassa W, Bakari M, Sandstrom E, et al. Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania. AIDS. 2004;18:433-438. (Pubitemid 38365870)
49. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet. 2006;368:1254-1259. (Pubitemid 44508698)
50. South African National AIDS Council. South African 2010 Clinical Guidelines for the Management of HIV and AIDS in Adults and Adolescents. Department of Health, Republic of South Africa. Available at: http://www.hiv911.org.za/wp-content/uploads/2010/04/2010-Adult- ART-Guidelines.pdf. Accessed November 20, 2010.
51. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4:e298.
52. Drusano GL, Stein DS. Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. Antimicrob Agents Chemother. 1998;42:358-361. (Pubitemid 28114445)
53. Keita-Perse O, Roger PM, Pradier C, et al. Do viral load and CD8 cell count at initiation of tritherapy influence the increase of CD4 T-cell count? AIDS. 1998;12:F175-F179. (Pubitemid 28479267)
54. Akileswaran C, Lurie MN, Flanigan TP, et al. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis. 2005;41: 376-385. (Pubitemid 41022117)
55. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895. (Pubitemid 38553709)
56. Laurent C, Ngom Gueye NF, Ndour CT, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr. 2005;38:14-17. (Pubitemid 40094112)
57. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
58. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997; 337:725-733. (Pubitemid 27417971)
59. National AIDS Control Programme. National Guidelines for the Clinical Management of HIV and AIDS, 2005. United Republic of Tanzania. Available at http://www.tanzaniahivaids.info/documents/Other%20Resource%20Documents/ Tz%20Clinical%20Guidelines%20for%20ART-2005.pdf. Accessed November 20, 2010.
60. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents, 2009. World Health Organization. Available at: http://www. who.int/hiv/pub/arv/rapid-advice-art.pdf. Accessed November 20, 2010.
61. Global Price Reporting Mechanism. World Health Organization. Available at: http://www.who.int/hiv/amds/gprm/en/index.html. Accessed November 20, 2010.
62. Thielman NM, Chu HY, Ostermann J, et al. Cost-effectiveness of free HIV voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania. Am J Public Health. 2006;96: 114-119. (Pubitemid 43042841)
63. Bertozzi S, Gutierrez JP, Opuni M, et al. Estimating resource needs for HIV/AIDS health care services in low-income and middle-income countries. Health Policy. 2004;69:189-200. (Pubitemid 38798442)
64. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22:475-481. (Pubitemid 35334817)
65. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403-1409. (Pubitemid 40563350)
66. Marks G, Crepaz N, Senterfitt JW, et al. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39:446-453. (Pubitemid 41003791)
67. Holtgrave D, McGuire J. Impact of counseling in voluntary counseling and testing programs for persons at risk for or living with HIV infection. Clin Infect Dis. 2007;45(Suppl 4):S240-243. (Pubitemid 351417223)
68. Holtgrave DR, Pinkerton SD. Can increasing awareness of HIV seropositivity reduce infections by 50% in the United States? J Acquir Immune Defic Syndr. 2007;44:360-363. (Pubitemid 46328356)
69. Sherr L, Lopman B, Kakowa M, et al. Voluntary counselling and testing: uptake, impact on sexual behaviour, and HIV incidence in a rural Zimbabwean cohort. AIDS. 2007;21:851-860. (Pubitemid 46573157)
70. Bunnell R, Opio A, Musinguzi J, et al. HIV transmission risk behavior among HIV-infected adults in Uganda: results of a nationally representative survey. AIDS. 2008;22:617-624. (Pubitemid 351640594)
71. Sweat M, Gregorich S, Sangiwa G, et al. Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. Lancet. 2000;356:113-121. (Pubitemid 30438512)
72. Bell E, Mthembu P, O'Sullivan S, et al. Sexual and reproductive health services and HIV testing: perspectives and experiences of women and men living with HIV and AIDS. Reprod Health Matters. 2007;15: 113-135. (Pubitemid 46771204)
73. MacPhail CL, Pettifor A, Coates T, et al. 'You must do the test to know your status': attitudes to HIV voluntary counseling and testing for adolescents among South African youth and parents. Health Educ Behav. 2008;35:87-104.
74. Dunn D, Woodburn P, Duong T, et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis. 2008;197:398-404. (Pubitemid 351263421)
75. Nsigaye R, Wringe A, Roura M, et al. From HIV diagnosis to treatment: evaluation of a referral system to promote and monitor access to antiretroviral therapy in rural Tanzania. J Int AIDS Soc. 2009;12:31.
76. McKinnon LR, Kimani M, Wachihi C, et al. Effect of baseline HIV disease parameters on CD4+ T cell recovery after antiretroviral therapy initiation in Kenyan women. PLoS One. 2010;5:e11434.
77. Khanna N, Opravil M, Furrer H, et al. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis. 2008;47:1093-1101.
78. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS. 2009;23:335-342.
79. Frenkel LM, Mullins JI. Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy? N Engl J Med. 2001;344:520-522. (Pubitemid 32164906)
80. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344: 7472-480.
81. Deeks SG, Barbour JD, Martin JN, et al. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946-953. (Pubitemid 30194478)